Abstract: The purpose of the present disclosure is to develop a new combination therapy that exerts a superior antitumor effect as compared to administration of an anti-CD26 antibody alone. In order to assess both the function of an immune checkpoint inhibitor and the antitumor effect of an anti-CD26 antibody, it is necessary to be provided with both a binding site on a human CD26 molecule and an immune system of the same lineage of a cancer cell. Thus, in order to acquire data of an immune checkpoint inhibitor and an anti-CD26 antibody, it is essential to perform analysis in a human immune system and a human tumor cell line. The present inventors have made an attempt to produce a human immune system mouse to be used as a model animal for confirming the effect of the combination between ICI and an anti-CD26 antibody, and have successfully produced a model mouse superior for generating human T-cells.

Abstract: A heat medium storage apparatus 10 including a heat medium tank defining an airtight inside space 22 and a preheating device 30 including a temperature adjusting portion 32 capable of melting the heat medium in solid form, wherein the temperature adjusting portion has a first part 32a and a second part 32b, when the temperature adjusting portion is provided so as to extend in the inside space, the first part is in contact with the heat medium so as to be covered with the heat medium, and the second part is provided so as to protrude into a gap area in which the heat medium is absent in the inside space and thereby the second part is exposed, and when the temperature adjusting portion is provided so as to extend in contact with the outer surface of the heat medium tank, the temperature adjusting portion extends in a contact manner so as to stretch from a first area corresponding to an area in contact with the heat medium in the inside space to a second area corresponding to an area not in contact with the heat

Abstract: Potential prognostic biomarkers for CD26-targeted therapy were identified based on phase I study data of a humanized anti-CD26 monoclonal antibody YS110 against CD26-expressing tumors. Using boxplot analysis, scatter plot analysis, Pearson's product-moment correlation/Spearman's rank-difference correlation, bar graph analysis, and receiver operating characteristic (ROC), a correlation between soluble CD26 titer variation and tumor volume variation by YS110 administration, RECIST criteria evaluation, and progression-free survival (PFS) were examined. Further, mechanism of serum soluble CD26 titer variation was confirmed by in vitro experiments. As a result, serum soluble CD26/DPP4 titer variation at an early stage of YS110 treatment was found for the first time as a predictive biomarker to evaluate a therapeutic effect.

Abstract: Provided is the present invention focusing on roles of IL-26 present in humans but not in mice by characterizing molecular mechanisms involved in interspecies differences in terms of efficacy of EGFR-TKI. The present inventors found that human cancers are exposed to IL-26 in a tumor microenvironment (TME), activating the EGFR-TKI bypass pathway, while suppression of IL-26 overcomes EGFR-TKI resistance in cancers. Furthermore, the present inventors identified EphA3 as a new functional receptor for IL-26 of TNBC. Therefore, the present invention provides a pharmaceutical composition for use in combination with an anticancer drug for treating cancer in a patient, the pharmaceutical composition containing a drug that reverses resistance to the anticancer drug by IL-26 as an active ingredient. Furthermore, the present invention provides a humanized anti-IL-26 antibody, and a therapeutic or preventive agent for refractory immune disorders or cancer using the antibody.

Abstract: According to one embodiment, a wearable device includes a first user interface and a display. An electronic device includes a second user interface and causes the display to display a home screen. The home screen displayed in the display is divided into variable-sized first, second, and third areas. One of the first area, the second area, and the third area is selectable by an operation from the first user interface or the second user interface. The selected area is larger than non-selected areas among the first area, the second area, and the third area. A central icon in the selected area is larger than other icons in the selected area. A display format of the central icon in the selected area is different from a display format of the other icons in the selected area.

Abstract: According to one embodiment, an electronic device includes a character input controller. The character input controller displays a software keyboard including a set of input areas. Each input area of the set includes objects each representing a character. The set of input areas is arranged adjacent to one another in a first direction. The character input controller moves an active input area in the first direction or in a second direction opposite to the first direction, in response to a first operation or a second operation, and changes a character of an active object displayed in the active input area into another character in the active input area, in response to a third operation or a fourth operation.

Abstract: According to one embodiment, an electronic apparatus includes an object display controller. The object display controller scrolls an object selection screen in a first direction when an operation device is operated to designate a second direction perpendicular to the first direction, by moving, in the second direction, a first object located at a first end of a line of a set of objects which are lined in the first direction on the object selection screen to disappear the first object from the object selection screen, and by displaying a second object different from any one of the set of objects to appear at a second end of the line of the set of objects on the object selection screen from a third direction opposite to the second direction.

Abstract: According to one embodiment, an electronic device includes a character input controller. The character input controller displays a software keyboard including a set of input areas. Each input area of the set includes objects each representing a character. The set of input areas is arranged adjacent to one another in a first direction. The character input controller moves an active input area in the first direction or in a second direction opposite to the first direction, in response to a first operation or a second operation, and changes a character of an active object displayed in the active input area into another character in the active input area, in response to a third operation or a fourth operation.

Abstract: According to one embodiment, a wearable device includes a first user interface and a display. An electronic device includes a second user interface and causes the display to display a home screen. The home screen displayed in the display is divided into variable-sized first, second, and third areas. One of the first area, the second area, and the third area is selectable by an operation from the first user interface or the second user interface. The selected area is larger than non-selected areas among the first area, the second area, and the third area. A central icon in the selected area is larger than other icons in the selected area. A display format of the central icon in the selected area is different from a display format of the other icons in the selected area.

Abstract: It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.

Abstract: It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.

Abstract: A method for purifying a pyrazolinone derivative comprising a step of mixing a solution containing a mixture containing the pyrazolinone derivative and a good solvent which can dissolve the pyrazolinone derivative with a poor solvent to crystallize the pyrazolinone derivative.

Abstract: An information processing apparatus includes: a wireless communication module which performs a wireless communication with a counterpart apparatus; a memory which stores a first application and a plurality of second applications, the first application for performing data communication with the counterpart apparatus through the wireless communication, and the second applications placed in a higher level than the first application; a controller which activates one of the second applications for the counterpart apparatus; and an indicator which makes an indication according to the wireless communication. The controller determines whether the activated one of the second applications is accessible the indicator.

Abstract: A mixing apparatus (10A) comprises a tubular mixing section (1) for mixing a combustible gas and a combustion supporting gas; a combustible gas supply port at one end (1a); a combustible gas transport device (3) for supplying the combustible gas into the tubular mixing section (1) from the combustible gas supply port; a mixed gas outlet port of the combustible gas and the combustion supporting gas at the other end (1b); and a combustion supporting gas supply tube (5) connected to the tubular mixing section (1) between the one end (1a) and the other end (1b) for supplying the combustion supporting gas into the tubular mixing section (1) from a combustion supporting gas supply port (5a). The combustible gas transport device (3) can control a flow velocity of the combustible gas at the combustion supporting gas supply port (5a) not less than a combustion velocity of the mixed gas.

Abstract: A mixer (10) for mixing a combustible gas and a combustion supporting gas comprises a tubular mixing section (1) which extends between one end (1a) having a combustible gas supply port (2) and the other end (1b) having a mixed gas discharge port (3); and a combustion supporting gas supply tube (4) which is inserted into the tubular mixing section (1) between the one end (1a) and the other end (1b) of the tubular mixing section (1) and has a combustion supporting gas supply port (5) at its tip (4a) to open towards the other end (1b) of the tubular mixing section (1). A juxta-tip part (4b) of the combustion supporting gas supply tube (4) has an outer shape tapered towards the combustion supporting gas supply port (5) at the tip (4a).

Abstract: A mixer (10) for mixing a combustible gas and a combustion supporting gas comprises a tubular mixing section (1) which extends between one end (1a) having a combustible gas supply port (2) and the other end (1b) having a mixed gas discharge port (3); and a combustion supporting gas supply tube (4) which is inserted into the tubular mixing section (1) between the one end (1a) and the other end (1b) of the tubular mixing section (1), is closed at its tip (4a), and has at least one combustion supporting gas supply port at its juxta-tip lateral part (4b). A central axis of the combustion supporting gas supply tube (4) at the juxta-tip lateral part (4b) is generally parallel to a longitudinal direction of the tubular mixing section (1).

Abstract: A method for purifying a pyrazolinone derivative comprising a step of mixing a solution containing a mixture containing the pyrazolinone derivative and a good solvent which can dissolve the pyrazolinone derivative with a poor solvent to crystallize the pyrazolinone derivative.

Abstract: According to one embodiment, an electronic apparatus comprises a communication device, a first controller, a second controller, and a player. The communication device has a close proximity wireless communication function. The first controller establishes connection between a wireless device and the communication device in a proximity state. The second controller connects the electronic apparatus to a server through the close proximity wireless communication function and a wireless communication function of the wireless device. The player plays a content received from the server through the close proximity wireless communication function and the wireless communication function of the wireless device, to halt playing the content when the proximity state is released during the playing, and resume playing the content when the proximity state is restored.

Abstract: An information processing apparatus includes: a wireless communication module which performs a wireless communication with a counterpart apparatus; a memory which stores a first application and a plurality of second applications, the first application for performing data communication with the counterpart apparatus through the wireless communication, and the second applications placed in a higher level than the first application; a controller which activates one of the second applications for the counterpart apparatus; and an indicator which makes an indication according to the wireless communication. The controller determines whether the activated one of the second applications is accessible the indicator.

Abstract: According to one exemplary embodiment, an information processing apparatus is provided with: a wireless communication module configured to perform a wireless communication with a counterpart communication apparatus that is detected to be in a given range from the wireless communication module; and a controller configured to control the wireless communication. The controller is configured to determine whether a condition for starting to perform the wireless communication is satisfied when the counterpart communication apparatus is detected by the wireless communication module, and to control the wireless communication module to start performing the wireless communication when the controller determines that the condition is satisfied.